Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus.
Key facts
- Who runs it
- Malmö University
- Where
- Sweden2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2/3
- People taking part
- 90 people, planned
- Started
- 18 May 2020
- Ended
- Dec 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Clobetasol Propionate
- Placebo/Klobetasol APL oral gel 0.025%
- Placebo
- Record updated
- 4 December 2024
Who can take part
- Age
- 40 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Symptomatic oral lichen planus
- Age above 40 years
Who cannot take part
- Active treatment with steroids or other immunomodulating substance
- Previous or actual oral malignancy
- Graft versus host disease
- Intraoral vesiculobullous diseases
- Allergy to Clobetasol
- Allergy to nystatin
- Lichenoid contact lesions
- Bacteria related lichenoid reaction
- Active antibiotic treatment
- Severe periodontitis
- Bad oral hygiene
- Biopsy not supporting OLP
- Not in menopause
- Participation in other medical study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The investigators want to study the effect of clobetasol in symptomatic oral lichen planus. The investigators will include 90 patients and randomly allocate them in three groups. The first group will receive active treatment both in the morning an evening. Group two receives placebo in the morning and active treatment in the evening. Group three will get placebo both in the morning and in the evening. All Groups will follow the same protocol with rinsing twice daily with test substance in conjunction with antifungal treatment. The patients will be controlled after two weeks and and again after another two weeks. A biopsy will be performed at inclusion and another biopsy will be taken at the end of the test period. Smears for candida will also be evaluated. The patients will be examined for changes in clinical appearance and will answer questions to note changes in symptoms. Our hypotheses: #Patients receiving clobetasol will have a better resolution af symptoms than those who got placebo. #Patients treated with clobetasol twice daily will have a faster relief of symptoms than patients just treated once daily. #The clinical signs of oral lichen planus will diminish more pronounced in the two groups given active treatment. #A majority of the OLP lesions were infected by candida. #Specific histological changes can be seen in the biopsies taken after clobetasol treatment compared to those taken before treatment.
The 3 groups in the trial
- Active/activeExisting treatment, for comparison
The one bottle for use in the morning has clobetasol-oral gel, and so does the bottle fore use in the evening. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
Treatment: Clobetasol Propionate
- Placebo/activeExisting treatment, for comparison
The bottle for use in the morning contains placebo and one for use in the evening contains clobetasol oral gel. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
Treatment: Placebo/Klobetasol APL oral gel 0.025%
- Placebo/placeboPlacebo, for comparison
Both bottles, the one for the morning and the one for use in the evening, contains placebo. The oral cavity will be rinsed with 5ml oral gel during 1 minute. Nystatin will be taken 1ml 4 times daily.
Treatment: Placebo
Results explained
A paper that names this trial, explained in plain words.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Topical Treatment With Clobetasol in Symptomatic Oral Lichen Planus. A Multicenter Placebo-controlled Randomized Clinical Trial.
- Publications
- Record updated
- 4 December 2024